BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics; iX Biopharma to Receive a $9M Upfront Plus Up to $239M in Milestone Payments Plus Royalties
Singapore Shares Close Marginally Lower; Nutryfarm Climbs 3% on Securing Order for 100 Containers of Durians
BRIEF-IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics
3 Stocks You Can Buy for Your Child’s Investment Account
IX Biopharma Signs Wafesil Licensing, Distribution Deal with China Resources Pharmaceutical Unit